statistiche ricercatore

TOSI, GIOVANNA

Distribuzione geografica

Continente	#
NA - Nord America	13.885
EU - Europa	8.932
AS - Asia	5.371
SA - Sud America	555
Continente sconosciuto - Info sul continente non disponibili	75
AF - Africa	69
OC - Oceania	7
Totale	28.894

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	13.596
IT - Italia	4.424
SG - Singapore	1.686
UA - Ucraina	1.557
CN - Cina	1.229
VN - Vietnam	892
TR - Turchia	654
DE - Germania	591
SE - Svezia	584
HK - Hong Kong	569
BR - Brasile	486
FI - Finlandia	477
FR - Francia	320
IE - Irlanda	301
GB - Regno Unito	254
RU - Federazione Russa	243
CA - Canada	189
IN - India	101
BD - Bangladesh	61
MX - Messico	58
PL - Polonia	43
JP - Giappone	41
BE - Belgio	33
NL - Olanda	26
ZA - Sudafrica	26
AR - Argentina	23
ES - Italia	23
IQ - Iraq	20
PK - Pakistan	15
LT - Lituania	13
KR - Corea	12
MA - Marocco	12
AE - Emirati Arabi Uniti	11
EC - Ecuador	10
PH - Filippine	10
VE - Venezuela	9
EU - Europa	8
SA - Arabia Saudita	8
CH - Svizzera	7
CO - Colombia	7
ID - Indonesia	7
IR - Iran	7
KE - Kenya	7
PY - Paraguay	7
CR - Costa Rica	6
CZ - Repubblica Ceca	6
HN - Honduras	6
MY - Malesia	6
NG - Nigeria	6
PE - Perù	6
UZ - Uzbekistan	6
JO - Giordania	5
TN - Tunisia	5
TW - Taiwan	5
AT - Austria	4
BY - Bielorussia	4
CL - Cile	4
DZ - Algeria	4
JM - Giamaica	4
LB - Libano	4
MD - Moldavia	4
NI - Nicaragua	4
PR - Porto Rico	4
AU - Australia	3
BB - Barbados	3
EG - Egitto	3
IL - Israele	3
KH - Cambogia	3
MT - Malta	3
NP - Nepal	3
NZ - Nuova Zelanda	3
PA - Panama	3
RS - Serbia	3
SV - El Salvador	3
TT - Trinidad e Tobago	3
BH - Bahrain	2
CI - Costa d'Avorio	2
DO - Repubblica Dominicana	2
EE - Estonia	2
GA - Gabon	2
GR - Grecia	2
GT - Guatemala	2
HR - Croazia	2
PS - Palestinian Territory	2
UY - Uruguay	2
AO - Angola	1
AZ - Azerbaigian	1
BG - Bulgaria	1
DK - Danimarca	1
GD - Grenada	1
GE - Georgia	1
GY - Guiana	1
KW - Kuwait	1
KY - Cayman, isole	1
KZ - Kazakistan	1
ME - Montenegro	1
MK - Macedonia	1
NO - Norvegia	1
OM - Oman	1
PT - Portogallo	1
Totale	28.821

Salva come PNG Salva come JPEG

Città	#
Milan	3.347
Ashburn	1.587
San Jose	1.279
Jacksonville	1.195
Singapore	933
Fairfield	928
Chandler	783
Woodbridge	610
Hong Kong	561
Council Bluffs	559
Wilmington	431
Ann Arbor	424
Houston	419
Izmir	406
Princeton	399
Seattle	391
Beijing	372
Dearborn	366
Dallas	307
Dublin	298
Nyköping	297
Cambridge	288
Dong Ket	268
Rome	242
Boardman	236
The Dalles	235
Lauterbourg	173
New York	151
San Mateo	138
Los Angeles	129
Toronto	111
Ho Chi Minh City	102
Santa Clara	101
São Paulo	94
Como	91
Chicago	89
Helsinki	84
Hanoi	79
San Diego	79
Orem	71
Ogden	70
Guangzhou	59
Munich	53
Düsseldorf	45
Chennai	40
Tokyo	40
Warsaw	36
Hefei	35
Mexico City	34
Verona	34
Brussels	31
London	31
Manchester	31
Nanjing	28
Frankfurt am Main	26
Montreal	26
Phoenix	26
Hangzhou	25
Norwalk	25
Atlanta	23
Boston	23
Shanghai	23
Turku	22
Brooklyn	21
Kunming	21
Buffalo	20
Denver	20
Pune	20
Amsterdam	19
Johannesburg	19
Jinan	18
San Francisco	18
Washington	18
Columbus	17
Falls Church	17
Stockholm	17
Da Nang	16
Fuzhou	16
Shenzhen	15
St Petersburg	15
Haiphong	14
Miami	14
Poplar	14
Naples	13
Philadelphia	12
Zhengzhou	12
Belo Horizonte	11
Charlotte	11
Las Vegas	11
Mumbai	11
Brasília	10
Nuremberg	10
Queens	10
Baghdad	9
Changsha	9
Curitiba	9
Kocaeli	9
Rio de Janeiro	9
Ankara	8
Bologna	8
Totale	19.960

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	282
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	261
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	243
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	243
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	225
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	224
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	223
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	220
The MHC class II transactivator: prey and hunter in infectious diseases	219
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	218
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	217
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	217
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	214
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	213
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	212
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	212
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	212
Autoimmunità e Malattie Autoimmuni	206
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	203
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	202
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	201
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	200
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	198
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis	197
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	191
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	189
Apparente dissociazione tra fenotipo DR e genotipo MHC di classe II in IDDM	188
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	187
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	185
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	185
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	184
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	183
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	181
A dual defensive role of CIITA against retroviral infections	181
Time-Resolved Förster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA	181
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	177
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	177
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	177
New approaches of cancer vaccination and cancer immunotherapy based on the optimal stimulation of tumor-specific, MHC class II-restricted CD4+ T helper cells	175
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	174
Associazione tra genotipo HLA-DQ e suscettibilità al Diabete insulino-Dipendente	173
MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?	171
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	170
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	170
Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers	169
Tax-1-mediated HTLV-1 replication and NF-kB activation is inhibited by the MHC-II transactivator CIITA	169
Tat protein is an HIV-1 encoded SS-chemochine homolog that promotes migrationand upregulates CCR3 on human FceRI+ cells	168
Analysis of microchimerism in thyroid autoimmune diseases	168
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	168
CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity	168
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	168
HLA-DQ genotype in early onset insulin dependent diabetes mellitus	166
MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to and affecting Tax-2 intracellular localization	164
Tax-1-mediated NF-kB activation is inhibited by the MHC-II transactivator CIITA	164
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes	164
The MHC-II transactivator CIITA inhibits Tat-mediated HIV-1 LTR transactivation and virus replication in human U937 monocytic cells	163
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	163
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	163
Distinct subcellular localization of HTLV-1 HBZ oncoprotein in the ATL leukemic and HAM/TSP patients.	163
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	162
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	162
Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters	161
Molecular typing of polymorphic genes by time-resolved fluorescence resonance energy transfer	161
Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication.	160
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	158
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	155
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	154
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	154
The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein	154
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	153
Role of the HLA-DQ genotype in IDDM susceptibility	153
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	152
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	152
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	151
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	150
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines	150
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	150
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	150
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1	150
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	150
The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-kappa B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein	150
The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for Insulin-Dependent Diabetes Mellitus	150
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	149
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	149
HLA-DQB1 typing of north east italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-Enzyme Immunoassay (DEIA)	148
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	148
The constitutive activation of NF-kB by HTLV-1 Tax-1 oncoprotein is inhibited by the MHC class II transactivator CIITA	148
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	147
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	147
Associazione tra HLA-DQB1 e diabete giovanile analizzata a livello molecolare per Southern e DEIA	147
HTLV-2 Tax-2 transactivator increases the expression and the function of its inhibitor CIITA, the master regulator of HLA-II gene transcription	147
Human HTLV-II virus directly acts on CD34+ hematopoietic precursors by increasing their survival potential. Envelope-associated HLA class II molecules reverse this effect	146
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	146
Expression of MHC class I and class II antigens in pancreatic adenocarcinomas	145
The MHC Class II transactivator, CIITA,is a viral restriction factor for human oncogenic retroviruses	145
Cellular and molecular aspects of immune response relevant to autoimmune diseases	144
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	143
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic Virus Type 1	142
Regulation of HLA antigen expression in HIV infected cells	140
Host-retrovirus interaction: role of CIITA in the inhibition of HTLV-1 replication and oncogenic potential	140
Totale	17.512

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	113.134
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	113.134

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.114	0	0	0	133	42	48	57	123	83	222	159	247
2022/2023	2.159	252	86	120	258	159	493	0	292	312	63	69	55
2023/2024	4.884	816	801	919	824	877	310	50	40	155	20	9	63
2024/2025	2.562	10	45	483	50	107	108	123	141	313	158	220	804
2025/2026	6.105	492	363	187	862	539	448	1.407	371	620	413	246	157
2026/2027	2.249	158	297	975	819	0	0	0	0	0	0	0	0
Totale													28.894